Please login to the form below

Not currently logged in
Email:
Password:

Nuvigil

This page shows the latest Nuvigil news and features for those working in and with pharma, biotech and healthcare.

Teva halts development of Nuvigil in bipolar disorder

Teva halts development of Nuvigil in bipolar disorder

Teva halts development of Nuvigil in bipolar disorder. Shelves plan to expand use of sleep disorder therapy. ... Teva Pharmaceutical has halted a programme investigating the use of its sleep disorder treatment Nuvigil to treat depression after

Latest news

  • Teva suffers setback as Nuvigil fails late-stage trial Teva suffers setback as Nuvigil fails late-stage trial

    Teva suffers setback as Nuvigil fails late-stage trial. Disappointing results in treating bipolar disorder but drug development continues. ... Some analysts believe the availability of Provigil generics will also dampen down sales growth of Nuvigil -

  • Teva sees Q2 profits leap as US business recovers

    Other strong performers were Parkinson's disease drug Azilect (rasagiline), up 36 per cent to $95m, while Cephalon products Treanda (bendamustine) for leukaemia and narcolepsy treatment Nuvigil  (armodafinil) added $139m and

  • Teva’s 2011 revenues boosted by Cephalon purchase

    Teva’ s 2011 revenues boosted by Cephalon purchase. Addition of Provigil, Treanda and Nuvigil help the generics specialist grow its branded products portfolio. ... These included inclusion chronic lymphocytic leukaemia treatment Treanda, which took in

  • Cephalon jet lag application rejected

    Cephalon jet lag application rejected. Cephalon has dropped its bid to get sleep disorder drug Nuvigil approved as a treatment for jet lag after a second rejection from the US FDA. ... Cephalon stressed that Nuvigil met the primary endpoints of pivotal

  • Cephalon posts record sales

    The quarter also saw Cephalon launch Nuvigil tablets and file a supplemental new drug application with the US Food and Drug Administration (FDA) for the drug as a treatment for excessive ... If Nuvigil is approved it will be the first acute indication

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics